Search

Your search keyword '"Baertsch, Marc‐Andrea"' showing total 23 results
Start Over Author "Baertsch, Marc‐Andrea"
23 results on '"Baertsch, Marc‐Andrea"'

1. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Author

Cirrincione, Anthony M., Poos, Alexandra M., Ziccheddu, Bachisio, Kaddoura, Marcella, Bärtsch, Marc-Andrea, Maclachlan, Kylee, Chojnacka, Monika, Diamond, Benjamin, John, Lukas, Reichert, Philipp, Huhn, Stefanie, Blaney, Patrick, Gagler, Dylan, Rippe, Karsten, Zhang, Yanming, Dogan, Ahmet, Lesokhin, Alexander M., Davies, Faith, Goldschmidt, Hartmut, Fenk, Roland, Weisel, Katja C., Mai, Elias K., Korde, Neha, Morgan, Gareth J., Usmani, Saad, Landgren, Ola, Raab, Marc S., Weinhold, Niels, and Maura, Francesco

Published
2024
Full Text
View/download PDF

3. A single-cell multi-omic and spatial atlas of B cell lymphomas reveals differentiation drives intratumor heterogeneity

Author

Fitzgerald, Donnacha, primary, Roider, Tobias, additional, Baertsch, Marc-Andrea, additional, Kibler, Artur, additional, Horlova, Anastasiia, additional, Chung, Erin, additional, Vöhringer, Harald, additional, Mathioudaki, Anna, additional, Budeus, Bettina, additional, Passerini, Verena, additional, Knoll, Mareike, additional, Mammen, Johannes, additional, Li, Linsha, additional, Caillé, Léandra, additional, Czernilofsky, Felix, additional, Bruch, Peter-Martin, additional, Liebers, Nora, additional, Meyer-Bender, Matthias, additional, Weigert, Oliver, additional, Zaugg, Judith, additional, Nolan, Garry, additional, Seifert, Marc, additional, Dietrich, Sascha, additional, and Huber, Wolfgang, additional

Published
2023
Full Text
View/download PDF

4. Multiple myeloma long-term survivors display sustained immune alterations decades after first line therapy

Author

Lutz, Raphael, primary, Grünschläger, Florian, additional, Simon, Malte, additional, Bauer, Marcus, additional, Yousefian, Schayan, additional, Beumer, Niklas, additional, Jopp-Saile, Lea, additional, Awwad, Mohamed H.S., additional, Steinbuss, Georg, additional, Sedlmeier, Anastasia, additional, Boch, Tobias, additional, Vonficht, Dominik, additional, Baertsch, Marc-Andrea, additional, Durie, Brian G.M., additional, Weinhold, Niels, additional, Raab, Marc S., additional, Wickenhauser, Claudia, additional, Trumpp, Andreas, additional, Müller-Tidow, Carsten, additional, Hübschmann, Daniel, additional, Brors, Benedikt, additional, Goldschmidt, Hartmut, additional, Imbusch, Charles D., additional, Hundemer, Michael, additional, and Haas, Simon, additional

Published
2023
Full Text
View/download PDF

5. Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

Author

Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Schlenzka, Jana, Salwender, Hans J., Munder, Markus, Gerecke, Christian, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Hillengass, Jens, Raab, Marc S., Merz, Maximilian, Baertsch, Marc-Andrea, Jauch, Anna, Hose, Dirk, Martin, Hans, Lindemann, Hans-Walter, Blau, Igor W., Scheid, Christof, Weisel, Katja C., Goldschmidt, Hartmut, and for the German-speaking Myeloma Multicenter Group (GMMG)

Published
2019
Full Text
View/download PDF

8. Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma

Author

Baertsch, Marc-Andrea, primary, Fougereau, Mathilde, additional, Hielscher, Thomas, additional, Sauer, Sandra, additional, Breitkreutz, Iris, additional, Jordan, Karin, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, Raab, Marc-Steffen, additional, Hillengass, Jens, additional, and Giesen, Nicola, additional

Published
2021
Full Text
View/download PDF

9. Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients

Author

Kriegsmann, Katharina, primary, Baertsch, Marc-Andrea, additional, Awwad, Mohamed H. S., additional, Merz, Maximilian, additional, Hose, Dirk, additional, Seckinger, Anja, additional, Jauch, Anna, additional, Becker, Natalia, additional, Benner, Axel, additional, Raab, Marc S., additional, Hillengass, Jens, additional, Bertsch, Uta, additional, Dürig, Jan, additional, Salwender, Hans Jürgen, additional, Hänel, Mathias, additional, Fenk, Roland, additional, Munder, Markus, additional, Weisel, Katja, additional, Müller-Tidow, Carsten, additional, Goldschmidt, Hartmut, additional, and Hundemer, Michael, additional

Published
2019
Full Text
View/download PDF

10. Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma.

Author

Baertsch, Marc-Andrea, Mai, Elias K., Hielscher, Thomas, Bertsch, Uta, Salwender, Hans J., Munder, Markus, Fuhrmann, Stephan, Dührsen, Ulrich, Brossart, Peter, Neben, Kai, Schlenzka, Jana, Kunz, Christina, Raab, Marc S., Hillengaß, Jens, Jauch, Anna, Seckinger, Anja, Hose, Dirk, Luntz, Steffen, Sonneveld, Pieter, and Lokhorst, Henk

Subjects
BORTEZOMIB, ANTINEOPLASTIC agents, DRUG efficacy, MULTIPLE myeloma treatment, STEM cell transplantation, CANCER chemotherapy, CLINICAL trials
Abstract

Lenalidomide (LEN) maintenance (MT) post autologous stem cell transplantation (ASCT) is standard of care in newly diagnosed multiple myeloma (MM) but has not been compared to other agents in clinical trials. We retrospectively compared bortezomib (BTZ; n = 138) or LEN (n = 183) MT from two subsequent GMMG phase III trials. All patients received three cycles of BTZ-based triplet induction and post-ASCT MT. BTZ MT (1.3 mg/m2 i.v.) was administered every 2 weeks for 2 years. LEN MT included two consolidation cycles (25 mg p.o., days 1–21 of 28 day cycles) followed by 10–15 mg/day for 2 years. The BTZ cohort more frequently received tandem ASCT (91% vs. 33%) due to different tandem ASCT strategies. In the LEN and BTZ cohort, 43% and 46% of patients completed 2 years of MT as intended (p = 0.57). Progression-free survival (PFS; HR = 0.83, p = 0.18) and overall survival (OS; HR = 0.70, p = 0.15) did not differ significantly with LEN vs. BTZ MT. Patients with

Published
2021
Full Text
View/download PDF

11. Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE

Author

Goldschmidt, Hartmut, Baertsch, Marc-Andrea, Schlenzka, Jana, Becker, Natalia, Habermehl, Christina, Hielscher, Thomas, Raab, Marc-Steffen, Hillengass, Jens, Sauer, Sandra, Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Hose, Dirk, Seckinger, Anja, Brossart, Peter, Goerner, Martin, Klein, Stefan, Schmidt-Hieber, Martin, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Haenel, Mathias, Martin, Hans, Lindemann, Hans W., Scheid, Christoph, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, and Weisel, Katja

Abstract

The role of salvage high-dose chemotherapy and autologous stem cell transplantation (sHDCT/ASCT) for relapsed and/or refractory multiple myeloma (RRMM) in the era of continuous novel agent treatment has not been defined. This randomized, open-label, phase III, multicenter trial randomized patients with 1st–3rd relapse of multiple myeloma (MM) to a transplant arm (n= 139) consisting of 3 Rd (lenalidomide 25 mg, day 1–21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles) reinduction cycles, sHDCT (melphalan 200 mg/m2), ASCT, and lenalidomide maintenance (10 mg/day) or to a control arm (n= 138) of continuous Rd. Median PFS was 20.7 months in the transplant and 18.8 months in the control arm (HR 0.87; 95% CI 0.65–1.16; p= 0.34). Median OS was not reached in the transplant and 62.7 months in the control arm (HR 0.81; 95% CI 0.52–1.28; p= 0.37). Forty-one patients (29%) did not receive the assigned sHDCT/ASCT mainly due to early disease progression, adverse events, and withdrawal of consent. Multivariate landmark analyses from the time of sHDCT showed superior PFS and OS (p= 0.0087/0.0057) in patients who received sHDCT/ASCT. Incorporation of sHDCT/ASCT into relapse treatment with Rd was feasible in 71% of patients and did not significantly prolong PFS and OS on ITT analysis while patients who received sHDCT/ASCT may have benefitted.

Published
2021
Full Text
View/download PDF

12. Spatial Dissection of the Bone Marrow Microenvironment in Multiple Myeloma By High Dimensional Multiplex Tissue Imaging

Author

Baertsch, Marc-Andrea, Brobeil, Alexander, Hickey, John, Haist, Maximilian, Poos, Alexandra Maria, Lu, Guolan, Kuswanto, Wilson, Schuerch, Christian, Voehringer, Harald, Huber, Wolfgang, Mechtersheimer, Gunhild, Mueller-Tidow, Carsten, Schirmacher, Peter, Weisel, Katja, Fenk, Roland, Goldschmidt, Hartmut, Goltsev, Yury, Raab, Marc S., Weinhold, Niels, and Nolan, Garry P.

Abstract

Introduction

Published
2023
Full Text
View/download PDF

13. Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse

Author

Baertsch, Marc-Andrea, Schlenzka, Jana, Hielscher, Thomas, Raab, Marc S., Sauer, Sandra, Merz, Maximilian, Mai, Elias K., Müller-Tidow, Carsten, Luntz, Steffen, Jauch, Anna, Brossart, Peter, Goerner, Martin, Klein, Stefan, Glass, Bertram, Reimer, Peter, Graeven, Ullrich, Fenk, Roland, Hänel, Mathias, von Metzler, Ivana, Hans W., Lindemann, Scheid, Christof, Nogai, Axel, Salwender, Hans, Noppeney, Richard, Besemer, Britta, Weisel, Katja, and Goldschmidt, Hartmut

Abstract

IntroductionThe randomized, controlled, multicenter, phase III GMMG ReLApsE trial compared lenalidomide/dexamethasone (Rd) re-induction, salvage high dose chemotherapy, autologous stem cell transplantation (HDCT/ASCT) and lenalidomide (R) maintenance with standard continuous Rd. We have previously reported the absence of a significant survival benefit in the primary analysis. However, landmark analyses from salvage HDCT performed due to the fact that ~30% of patients in the HDCT arm did not receive salvage HDCT/ASCT suggested a survival benefit in patients undergoing salvage HDCT/ASCT. Here we report long term follow up results from the GMMG ReLApsE trial.

Published
2023
Full Text
View/download PDF

14. Enhanced Control of Oncolytic Measles Virus Using MicroRNA Target Sites

Author

Leber, Mathias Felix, primary, Baertsch, Marc-Andrea, additional, Anker, Sophie Caroline, additional, Henkel, Luisa, additional, Singh, Hans Martin, additional, Bossow, Sascha, additional, Engeland, Christine E., additional, Barkley, Russell, additional, Hoyler, Birgit, additional, Albert, Jessica, additional, Springfeld, Christoph, additional, Jäger, Dirk, additional, von Kalle, Christof, additional, and Ungerechts, Guy, additional

Published
2018
Full Text
View/download PDF

15. Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Author

Baertsch, Marc‐Andrea, Hundemer, Michael, Hillengass, Jens, Goldschmidt, Hartmut, Raab, Marc S., and Baertsch, Marc-Andrea

Subjects
MONOCLONAL antibodies, MULTIPLE myeloma, NEOVASCULARIZATION inhibitors, SURVIVAL analysis (Biometry), PHARMACODYNAMICS, THALIDOMIDE, THERAPEUTICS
Abstract

In multiple myeloma (MM), the synergy between immunomodulatory drugs (IMiDs) and monoclonal antibodies (MABs) has been demonstrated in several pivotal trials. However, disease refractory to either class of compounds remains a major therapeutic challenge. We here report on 3 heavily pretreated MM patients who were refractory to pomalidomide as well as to MABs against CD38 (daratumumab) or CD20 (rituximab), respectively, but who responded to retreatment with the same agents in combination. Responses were durable with PFS of 7, 10 (ongoing), and 30 months from initiation of combination treatment. The combination of IMiDs with MABs directed against MM cell surface antigens can overcome refractoriness to both agents. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

16. Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice.

Author

Baertsch, Marc‐Andrea, Hillengass, Jens, Blocka, Joanna, Schönland, Stefan, Hegenbart, Ute, Goldschmidt, Hartmut, Raab, Marc S., and Baertsch, Marc-Andrea

Subjects
ENZYME inhibitors, HYDROXY acids, INDOLE compounds, PHARMACODYNAMICS, THERAPEUTICS
Abstract

The histone deacetylase inhibitor panobinostat has shown efficacy in phase-II and phase-III trials for multiple myeloma and has recently received market approval in combination with bortezomib and dexamethasone. Here, we retrospectively report our single center experience with panobinostat/bortezomib/dexamethasone (FVD) in a heavily pretreated patient population (n = 24) with a high degree of refractoriness to proteasome inhibitors (PI) and immunomodulatory drugs (IMiD). Median age was 67 years (range 49-87) and the median number of prior therapies was 5 (range 2-17). Fourteen patients (58%) had high-risk cytogenetic aberrations. Thirteen (54%) and 21 (88%) patients were refractory to PIs and IMiDs, respectively. Twelve patients (50%) were refractory to bortezomib and 7 (29%) to carfilzomib; 6 patients (25%) were refractory to both bortezomib and carfilzomib. In 21 patients evaluable for response, overall response rate (ORR; ≥PR) was 33% (7/21) and 81% (17/21) achieved at least stable disease. Median progression-free survival (PFS) and overall survival were 3.5 and 9.8 months, respectively. Significant differences between bortezomib-sensitive and -refractory patients were observed. In bortezomib-sensitive patients, median PFS was 6.3 months compared to 2.3 months in bortezomib-refractory patients (P < .001). Median overall survival was not reached vs 4.8 months (P = .046) in bortezomib-sensitive and bortezomib-refractory patients, respectively. The only patient refractory to carfilzomib but sensitive to bortezomib achieved very good partial remission and PFS of 6.3 months, suggesting discrete mechanisms of resistance to different PIs. As expected, thrombocytopenia and fatigue/asthenia occurred in nearly all patients (96% and 83%, respectively). Diarrhea was observed in only 19% of patients which compares favorably with the high rates of diarrhea reported in the PANORAMA trials. With panobinostat dose reductions in 67% of patients, FVD was tolerated by the majority of patients. In conclusion, FVD showed efficacy in a heavily pretreated, high-risk multiple myeloma population with a high degree of patients refractory to novel agents including PIs. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

20. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE

Author

Baertsch, Marc-Andrea, primary, Schlenzka, Jana, additional, Lisenko, Katharina, additional, Krzykalla, Julia, additional, Becker, Natalia, additional, Weisel, Katja, additional, Noppeney, Richard, additional, Martin, Hans, additional, Lindemann, Hans W., additional, Haenel, Mathias, additional, Nogai, Axel, additional, Scheid, Christof, additional, Salwender, Hans, additional, Fenk, Roland, additional, Graeven, Ullrich, additional, Reimer, Peter, additional, Schmidt-Hieber, Martin, additional, Goerner, Martin, additional, Schmidt-Wolf, Ingo G. H., additional, Klein, Stefan, additional, Ho, Anthony D., additional, Goldschmidt, Hartmut, additional, and Wuchter, Patrick, additional

Published
2017
Full Text
View/download PDF

21. Evaluation of Stem Cell Mobilization in Patients with Multiple Myeloma after Lenalidomide-Based Induction Chemotherapy within the GMMG-HD6 Trial

Author

Wuchter, Patrick, primary, Bertsch, Uta, additional, Salwender, Hans-Juergen, additional, Munder, Markus, additional, Haenel, Mathias, additional, Benner, Axel, additional, Becker, Natalia, additional, Fenk, Roland, additional, Duerig, Jan, additional, Blau, Igor Wolfgang, additional, Lisenko, Katharina, additional, Hillengass, Jens, additional, Raab, Marc S., additional, Baertsch, Marc Andrea, additional, Seidel-Glaetzer, Andrea, additional, Ho, Anthony D, additional, Graeven, Ullrich, additional, Scheid, Christof, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2016
Full Text
View/download PDF

22. Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma

Author

Baertsch, Marc-Andrea, primary, Schlenzka, Jana, additional, Mai, Elias K., additional, Merz, Maximilian, additional, Hillengaß, Jens, additional, Raab, Marc S., additional, Hose, Dirk, additional, Wuchter, Patrick, additional, Ho, Anthony D., additional, Jauch, Anna, additional, Hielscher, Thomas, additional, Kunz, Christina, additional, Luntz, Steffen, additional, Klein, Stefan, additional, Schmidt-Wolf, Ingo G. H., additional, Goerner, Martin, additional, Schmidt-Hieber, Martin, additional, Reimer, Peter, additional, Graeven, Ullrich, additional, Fenk, Roland, additional, Salwender, Hans, additional, Scheid, Christof, additional, Nogai, Axel, additional, Haenel, Mathias, additional, Lindemann, Hans W., additional, Martin, Hans, additional, Noppeney, Richard, additional, Weisel, Katja, additional, and Goldschmidt, Hartmut, additional

Published
2016
Full Text
View/download PDF

23. Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Author

Baertsch, Marc-Andrea, Kriegsmann, Katharina, Pavel, Petra, Bruckner, Thomas, Hundemer, Michael, Kriegsmann, Mark, Ho, Anthony D., Goldschmidt, Hartmut, and Wuchter, Patrick

Subjects
*BLOOD platelets, *BLOOD transfusion, *LEUCOCYTES, *BLOOD cell count, *BONE marrow
Abstract

Background: A low platelet count before mobilization has recurrently been identified as risk factor for poor mobilization. Methods: To determine the relevance of this finding for peripheral blood stem cell (PBSC) mobilization, including pre-emptive or rescue plerixafor in the case of poor mobilization, we retrospectively analyzed all patients undergoing PBSC collection at our institution between January 2014 and December 2015 (n = 380). Results: In total, 99% of the patients (377/380) successfully collected a minimum of 2 × 106 CD34+ cells/kg body weight sufficient for a single transplant. Rescue or pre-emptive plerixafor was administered to 11% of the patients (42/380). No correlations between the platelet count before mobilization and the number of peripheral blood CD34+ cells or the CD34+ cell collection result were detected in the entire population or the subgroups according to diagnosis (newly diagnosed multiple myeloma, relapsed multiple myeloma, lymphoma, amyloid light-chain amyloidosis, sarcoma, or germ cell tumor). However, patients requiring pre-emptive or rescue plerixafor had a significantly lower platelet count before mobilization (217/nl vs. 245/nl; p = 0.004). Conclusion: With the current state of the art PBSC mobilization strategies, the platelet count before mobilization was not associated with the CD34+ cell collection result but was associated with the need for pre-emptive or rescue application of plerixafor. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results